CNR1 and cancer: Studies involving cancer cell lines showed that tamoxifen, a hydroxylated, biologically active metabolite, and several other newer SERMs, act as inverse agonists for CB1-R and CB2-R with considerable affinity (between nM and low μM concentrations).